Eupraxia Pharmaceuticals Inc. (EPRX.TO)

CAD 4.59

(-2.34%)

Market Cap (In CAD)

163.5 Million

Revenue (In CAD)

-

Net Income (In CAD)

-37.39 Million

Avg. Volume

16.89 Thousand

Currency
CAD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.07-7.64
PE
-
EPS
-
Beta Value
1.228
ISIN
CA29842P1053
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. James A. Helliwell FRCPC, M.D.
Employee Count
-
Website
https://www.eupraxiapharma.com
Ipo Date
2021-03-09
Details
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.